Sera Prognostics (SERA) Set to Announce Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

Shares of Sera Prognostics stock traded down $1.26 during trading on Wednesday, hitting $10.43. 151,320 shares of the stock were exchanged, compared to its average volume of 220,134. The stock's fifty day moving average is $9.51 and its 200 day moving average is $6.37. The stock has a market cap of $338.20 million, a PE ratio of -8.99 and a beta of 1.49. Sera Prognostics has a 12 month low of $1.52 and a 12 month high of $12.35.

Insider Transactions at Sera Prognostics

In other news, insider John J. Boniface sold 24,474 shares of the company's stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $9.04, for a total transaction of $221,244.96. Following the completion of the transaction, the insider now owns 139,771 shares in the company, valued at $1,263,529.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, General Counsel Benjamin Jackson sold 5,665 shares of the company's stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $45,489.95. Following the completion of the sale, the general counsel now owns 152,035 shares of the company's stock, valued at $1,220,841.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John J. Boniface sold 24,474 shares of the company's stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $9.04, for a total transaction of $221,244.96. Following the completion of the sale, the insider now directly owns 139,771 shares of the company's stock, valued at $1,263,529.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 141,335 shares of company stock worth $1,255,192. Insiders own 15.60% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.